Table 6.
Therapeutic effects and potential pathways of jujube in the prevention and treatment for hepatopathy.
| Diseases | Model | Type | Administration | Effects | Refs. |
|---|---|---|---|---|---|
| Non-alcoholic liver injury | Mice: CCl4, acetaminophen |
In vivo | i.g.: 100, 200, 400 mg/kg (flavonoids) p.o.: 100, 200, 400 mg/kg (polysaccharides) |
↑CAT ↑NRF2 ↑SOD, GSH-Px, GSH, NQO1 ↓NF-κB ↓MDA, lipid peroxidation ↓ALT, AST, ALP, TB, LDH ↓TNF-α, IL-6, IL-1β, IL-10 |
[8,9,12,58] |
| HepG2 cells: CCl4 | In vitro | 100 μg/mL (root bark extract) |
|||
| Patients: tuberculosis | Clinical | 10 mL/d (jujube syrup) |
↑QOL ↓Cough ↓Hepatotoxicity |
||
| Alcoholic liver disease | Mice: alcohol | In vivo | i.g.: 0.02 g/kg |
↑GSH ↑Cell viability ↑NRF2, HO-1, NQO1, GCLC ↓AST, ALT ↓MDA, ROS ↓CYP2E1, TNF-α ↓Histological lesions |
[61] |
| HepG2 cells: alcohol | In vitro | 100 μg/mL | |||
| Jaundice | Patients: jaundiced newborns |
Clinical | 1 mg/kg | ↓Bilirubin | [60] |
Notes: CAT, catalase; GSH-Px, glutathione peroxidase; NQO1, NAD(P)H: quinone oxidoreductase 1; ALP, alkaline phosphatase; TB, total bilirubin; LDH, lactic dehydrogenase; QOL, quality of life; GCLC, glutamate-cysteine ligase; CYP2E1, cytochrome p450 2E1.